OBJECTIVE: Lower limb peripheral arterial disease in the symptomatic stage has a significant effect on patients´ functional disability. Before an intervention, an imaging diagnostic examination is necessary to determine the extent of the disability. This study evaluates cost-effectiveness of duplex ultrasonography (DUS), digital subtraction angiography (DSA), computed tomography angiography (CTA) and magnetic resonance angiography (MRA) in the diagnostics of symptomatic patients with lower limb peripheral arterial disease indicated for endovascular or surgical intervention. METHODS: Discrete event simulation was used to capture lifetime costs and effects. Costs were calculated from the perspective of the health care payer, and the effects were calculated as quality-adjusted life year's (QALY's). The cost-effectiveness analysis was performed to pairwise compare CTA, MRA and DSA with DUS as the baseline diagnostic modality. A scenario analysis and probabilistic sensitivity analysis were carried out to evaluate the robustness of the results. RESULTS: In the basic case, the DUS diagnostic was the least expensive modality, at a cost of EUR 10,778, compared with EUR 10,804 for CTA, EUR 11,184 for MRA, and EUR 11,460 for DSA. The effects of DUS were estimated at 5.542 QALYs compared with 5.554 QALYs for both CTA and MRA, and 5.562 QALYs for DSA. The final incremental cost-effectiveness ratio (ICER) value of all evaluated modalities was below the cost-effectiveness threshold whereas CTA has the lowest ICER of EUR 2,167 per QALY. However, the results were associated with a large degree of uncertainty, because iterations were spread across all cost-effectiveness quadrants in the probabilistic sensitivity analysis. CONCLUSION: For imaging diagnosis of symptomatic patients with lower limb peripheral arterial disease, CTA examination appears to be the most cost-effective strategy with the best ICER value. Baseline diagnostics of the DUS modality has the lowest costs, but also the lowest effects. DSA achieves the highest QALYs, but it is associated with the highest costs.

Department of Biomedical Technology Faculty of Biomedical Engineering Czech Technical University Prague Prague Czechia

See more in PubMed

Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. (2015) 116:1509–26. doi: 10.1161/CIRCRESAHA.116.303849 PubMed DOI

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-society consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. (2007) 45:S5–S67. doi: 10.1016/j.jvs.2006.12.037 PubMed DOI

Fowkes FGR, Aboyans V, Fowkes FJI, McDermott MM, Sampson UKA, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. (2017) 14:156–70. doi: 10.1038/nrcardio.2016.179, PMID: PubMed DOI

Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. . 2016 AHA/ACC guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. (2017) 135:e686–725. doi: 10.1161/CIR.0000000000000470 PubMed DOI PMC

Martelli E, Enea I, Zamboni M, Federici M, Bracale UM, Sangiorgi G, et al. . Focus on the Most common Paucisymptomatic Vasculopathic population, from diagnosis to secondary prevention of complications. Diagnostics. (2023) 13:2356. doi: 10.3390/diagnostics13142356 PubMed DOI PMC

Aboyans V, Ricco JB, Bartelink MLEL, Björck M, Brodmann M, Cohnert T, et al. . 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. (2018) 39:763–816. doi: 10.1093/eurheartj/ehx095, PMID: PubMed DOI

Pollak AW, Norton PT, Kramer CM. Multimodality imaging of lower extremity peripheral arterial disease: current role and future directions. Circ Cardiovasc Imaging. (2012) 5:797–807. doi: 10.1161/CIRCIMAGING.111.970814, PMID: PubMed DOI PMC

Kamenský V, Rogalewicz V, Gajdoš O, Donin G. Discrete event simulation model for cost-effectiveness evaluation of screening for asymptomatic patients with lower extremity arterial disease. IJERPH. (2022) 19:11792. doi: 10.3390/ijerph191811792, PMID: PubMed DOI PMC

RStudio Team . RStudio: Integrated development environment for R [internet]. Boston: RStudio, PBC; (2021).

ČSÚ - Věková struktura . Sčítání (2021). Available at: https://scitani.gov.cz/vekova-struktura

Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta. (1954) 21:499–533. PubMed

Corro Ramos I, Hoogendoorn M, Rutten-van Mölken MPMH. How to address uncertainty in health economic discrete-event simulation models: an illustration for chronic obstructive pulmonary disease. Med Decis Mak. (2020) 40:619–32. doi: 10.1177/0272989X20932145, PMID: PubMed DOI PMC

Di Minno G, Spadarella G, Cafaro G, Petitto M, Lupoli R, Di Minno A, et al. . Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. Ann Med. (2014) 46:475–89. doi: 10.3109/07853890.2014.932618, PMID: PubMed DOI PMC

SP-CAU-028 - W: Postup pro posuzování analýzy nákladové efektivity. Státní Ústav pro Kontrolu Léčiv; (2022). Available at:https://www.sukl.cz/file/97943_1_1/download/

Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, Wong JB. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force–7. Med Decis Mak. (2012) 32:733–43. doi: 10.1177/0272989X12454579 PubMed DOI

Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group–6. Med Decis Mak. (2012) 32:722–32. doi: 10.1177/0272989X12458348 PubMed DOI

Bertoldi EG, Stella SF, Rohde LEP, Polanczyk CA. Cost-effectiveness of anatomical and functional test strategies for stable chest pain: public health perspective from a middle-income country. BMJ Open. (2017) 7:e012652. doi: 10.1136/bmjopen-2016-012652, PMID: PubMed DOI PMC

Tappenden P, Chilcott J, Brennan A, Squires H, Stevenson M. Whole disease modeling to inform resource allocation decisions in Cancer: a methodological framework. Value Health. (2012) 15:1127–36. doi: 10.1016/j.jval.2012.07.008 PubMed DOI

Yin D, Baum RA, Carpenter JP, Langlotz CP, Pentecost MJ. Cost-effectiveness of MR angiography in cases of limb-threatening peripheral vascular disease. Radiology. (1995) 194:757–64. doi: 10.1148/radiology.194.3.7862975 PubMed DOI

Visser K, Kuntz KM, Donaldson MC, Scott Gazelle G, Hunink MGM. Pretreatment imaging workup for patients with intermittent claudication: a cost-effectiveness analysis. J Vasc Interv Radiol. (2003) 14:53–62. doi: 10.1097/01.RVI.0000052291.26939.82 PubMed DOI

Visser K, Kock MCJM, Kuntz KM, Donaldson MC, Gazelle GS, Myriam Hunink MG. Cost-effectiveness targets for multi–detector row CT angiography in the work-up of patients with intermittent claudication. Radiology. (2003) 227:647–56. doi: 10.1148/radiol.2273020441, PMID: PubMed DOI

Visser K, de Vries SO, Kitslaar PJEHM, van Engelshoven JMA, Hunink MGM. Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in the Netherlands. Eur J Vasc Endovasc Surg. (2003) 25:213–23. doi: 10.1053/ejvs.2002.1838, PMID: PubMed DOI

Collins R, Cranny G, Burch J, Aguiar-Ibáñez R, Craig D, Wright K, et al. . A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease. Health Technol Assess. (2007) 1:iii-iv, xi-xiii, 1-184. doi: 10.3310/hta11200, PMID: PubMed DOI

Vaidya A, Joore MA, ten Cate-Hoek AJ, ten Cate H, Severens JL. Screen or not to screen for peripheral arterial disease: guidance from a decision model. BMC Public Health. (2014) 14:89. doi: 10.1186/1471-2458-14-89, PMID: PubMed DOI PMC

Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, et al. . Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vasc Med. (2018) 23:97–106. doi: 10.1177/1358863X17745371, PMID: PubMed DOI PMC

Lindholt JS, Søgaard R. Clinical benefit, harm, and cost effectiveness of screening men for peripheral artery disease: a Markov model based on the VIVA trial. Eur J Vasc Endovasc Surg. (2021) 61:971–9. doi: 10.1016/j.ejvs.2021.02.039 PubMed DOI

Lord J, Willis S, Eatock J, Tappenden P, Trapero-Bertran M, Miners A, et al. . Economic modelling of diagnostic and treatment pathways in National Institute for health and care excellence clinical guidelines: the modelling algorithm pathways in guidelines (MAPGuide) project. Health Technol Asses. (2013) 17:v-vi, 1-192. doi: 10.3310/hta17580, PMID: PubMed DOI PMC

Tappenden P, Chilcott J, Brennan A, Squires H, Glynne-Jones R, Tappenden J. Using whole disease modeling to inform resource allocation decisions: economic evaluation of a clinical guideline for colorectal Cancer using a single model. Value Health. (2013) 16:542–53. doi: 10.1016/j.jval.2013.02.012, PMID: PubMed DOI

Simpson EL, Kearns B, Stevenson MD, Cantrell AJ, Littlewood C, Michaels JA. Enhancements to angioplasty for peripheral arterial occlusive disease: systematic review, cost-effectiveness assessment and expected value of information analysis. Health Technol Assess. (2014) 18:1–252. doi: 10.3310/hta18100, PMID: PubMed DOI PMC

Hunink MG, Wong JB, Donaldson MC, Meyerovitz MF, de Vries J, Harrington DP. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA. (1995) 274:165–71. doi: 10.1001/jama.1995.03530020083037 PubMed DOI

Kearns BC, Thomas SM. Cost-effectiveness of superficial femoral artery endovascular interventions in the UK and Germany: a modelling study. BMJ Open. (2017) 7:e013460. doi: 10.1136/bmjopen-2016-013460, PMID: PubMed DOI PMC

Zákony pro lidi. 428/2020 Sb. Vyhláška o stanovení hodnot bodu, výše úhrad hrazených služeb a regulačních omezení pro rok (2021). Available at:https://www.zakonyprolidi.cz/cs/2020-428

Státní ústav pro kontrolu léčiv. Available at: https://www.sukl.cz/modules/medication/search.php (Accessed May 29, 2022).

Janssen MF, Szende A, Cabases J, Ramos-Goñi JM, Vilagut G, König HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ. (2019) 20:205–16. doi: 10.1007/s10198-018-0955-5, PMID: PubMed DOI PMC

de Vries M, Ouwendijk R, Kessels AG, de Haan MW, Flobbe K, Hunink MGM, et al. . Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. J Vasc Surg. (2005) 41:261–8. doi: 10.1016/j.jvs.2004.11.022, PMID: PubMed DOI

Sculpher M, Michaels J, Mckenna M, Minor J. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care. (1996) 12:104–25. doi: 10.1017/S0266462300009430, PMID: PubMed DOI